724 related articles for article (PubMed ID: 26608590)
21. Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial.
Nashan B; Schemmer P; Braun F; Dworak M; Wimmer P; Schlitt H
Trials; 2015 Mar; 16():118. PubMed ID: 25873064
[TBL] [Abstract][Full Text] [Related]
22. Late conversion from tacrolimus to a belatacept-based immuno-suppression regime in kidney transplant recipients improves renal function, acid-base derangement and mineral-bone metabolism.
Schulte K; Vollmer C; Klasen V; Bräsen JH; Püchel J; Borzikowsky C; Kunzendorf U; Feldkamp T
J Nephrol; 2017 Aug; 30(4):607-615. PubMed ID: 28540602
[TBL] [Abstract][Full Text] [Related]
23. A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients.
Chadban SJ; Eris JM; Kanellis J; Pilmore H; Lee PC; Lim SK; Woodcock C; Kurstjens N; Russ G;
Transpl Int; 2014 Mar; 27(3):302-11. PubMed ID: 24279685
[TBL] [Abstract][Full Text] [Related]
24. Improvement of renal graft function after conversion from a calcineurin inhibitor including immunosuppression to a mycophenolate sodium including regimen: a 4-year follow-up.
Heeg MH; Mueller GA; Bramlage C; Homayounfar K; Muehlhausen J; Leha A; Koziolek MJ
Transplant Proc; 2013; 45(1):142-7. PubMed ID: 23375288
[TBL] [Abstract][Full Text] [Related]
25. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study.
Gustafsson F; Andreassen AK; Andersson B; Eiskjær H; Rådegran G; Gude E; Jansson K; Solbu D; Karason K; Arora S; Dellgren G; Gullestad L;
Transplantation; 2020 Jan; 104(1):154-164. PubMed ID: 30893292
[TBL] [Abstract][Full Text] [Related]
26. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
Budde K; Becker T; Arns W; Sommerer C; Reinke P; Eisenberger U; Kramer S; Fischer W; Gschaidmeier H; Pietruck F;
Lancet; 2011 Mar; 377(9768):837-47. PubMed ID: 21334736
[TBL] [Abstract][Full Text] [Related]
27. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure.
Groetzner J; Kaczmarek I; Schulz U; Stegemann E; Kaiser K; Wittwer T; Schirmer J; Voss M; Strauch J; Wahlers T; Sohn HY; Wagner F; Tenderich G; Stempfle HU; Mueller-Ehmsen J; Schmid C; Vogeser M; Koch KC; Reichenspurner H; Daebritz S; Meiser B; Reichart B;
Transplantation; 2009 Mar; 87(5):726-33. PubMed ID: 19295318
[TBL] [Abstract][Full Text] [Related]
28. Outcomes of Conversion From Calcineurin Inhibitor to Belatacept-based Immunosuppression in HLA-sensitized Kidney Transplant Recipients.
Sethi S; Najjar R; Peng A; Choi J; Lim K; Vo A; Jordan SC; Huang E
Transplantation; 2020 Jul; 104(7):1500-1507. PubMed ID: 31568398
[TBL] [Abstract][Full Text] [Related]
29. Conversion from everolimus with low-exposure cyclosporine to everolimus with mycophenolate sodium maintenance therapy in kidney transplant recipients: a randomized, open-label multicenter study.
Albano L; Alamartine E; Toupance O; Moulin B; Merville P; Rerolle JP; Tetaz R; Moal MC; Kamar N; Legendre C; Quéré S; Di Giambattista F; Terpereau A; Dantal J
Ann Transplant; 2012; 17(1):58-67. PubMed ID: 22466910
[TBL] [Abstract][Full Text] [Related]
30. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study.
Holdaas H; Rostaing L; Serón D; Cole E; Chapman J; Fellstrøm B; Strom EH; Jardine A; Midtvedt K; Machein U; Ulbricht B; Karpov A; O'Connell PJ;
Transplantation; 2011 Aug; 92(4):410-8. PubMed ID: 21697773
[TBL] [Abstract][Full Text] [Related]
31. Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients.
Groetzner J; Kaczmarek I; Landwehr P; Mueller M; Daebritz S; Lamm P; Meiser B; Reichart B
Eur J Cardiothorac Surg; 2004 Mar; 25(3):333-41. PubMed ID: 15019657
[TBL] [Abstract][Full Text] [Related]
32. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant.
Rivelli RF; Gonçalves RT; Leite M; Santos MA; Delgado AG; Cardoso LR; Takiya CM
Nephrology (Carlton); 2015 Mar; 20(3):168-76. PubMed ID: 25404086
[TBL] [Abstract][Full Text] [Related]
33. Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial.
Weir MR; Pearson TC; Patel A; Peddi VR; Kalil R; Scandling J; Chan L; Baliga P; Melton L; Mulgaonkar S; Waid T; Schaefer H; Youssef N; Anandagoda L; McCollum D; Lawson S; Gordon R
Transplantation; 2017 Jan; 101(1):157-165. PubMed ID: 26950714
[TBL] [Abstract][Full Text] [Related]
34. Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study.
Uchida J; Machida Y; Iwai T; Kuwabara N; Kabei K; Naganuma T; Kumada N; Kawashima H; Nakatani T
Clin Transplant; 2014 Jan; 28(1):80-7. PubMed ID: 24329776
[TBL] [Abstract][Full Text] [Related]
35. Renal function to 5 years after late conversion of kidney transplant patients to everolimus: a randomized trial.
Budde K; Sommerer C; Rath T; Reinke P; Haller H; Witzke O; Suwelack B; Baeumer D; Sieder C; Porstner M; Arns W
J Nephrol; 2015 Feb; 28(1):115-23. PubMed ID: 25192833
[TBL] [Abstract][Full Text] [Related]
36. Limitations of current liver transplant immunosuppressive regimens: renal considerations.
Zhang W; Fung J
Hepatobiliary Pancreat Dis Int; 2017 Feb; 16(1):27-32. PubMed ID: 28119255
[TBL] [Abstract][Full Text] [Related]
37. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
[TBL] [Abstract][Full Text] [Related]
38. Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial.
Budde K; Prashar R; Haller H; Rial MC; Kamar N; Agarwal A; de Fijter JW; Rostaing L; Berger SP; Djamali A; Leca N; Allamassey L; Gao S; Polinsky M; Vincenti F
J Am Soc Nephrol; 2021 Dec; 32(12):3252-3264. PubMed ID: 34706967
[TBL] [Abstract][Full Text] [Related]
39. Safety and immunologic benefits of conversion to sirolimus in kidney transplant recipients with long-term exposure to calcineurin inhibitors.
Yu JH; Kim KW; Kim BM; Chung BH; Cho ML; Choi BS; Park CW; Kim YS; Yang CW
Korean J Intern Med; 2016 May; 31(3):552-9. PubMed ID: 26968190
[TBL] [Abstract][Full Text] [Related]
40. Calcineurin-inhibitor free immunosuppression after lung transplantation - a single center case-control study in 51 patients converted to Mechanistic Target of Rapamycin (mTOR) inhibitors.
Gottlieb J; Fischer B; Schupp JC; Golpon H
PLoS One; 2023; 18(5):e0284653. PubMed ID: 37200246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
